Treatment of Schamberg's disease with pentoxifylline--therapeutic trial.
نویسندگان
چکیده
Twenty patients with Schamberg's disease were started on pentoxifylline (400 mg once daily) for a period of 8 weeks. Improvement was assessed at 2 weekly intervals by two observers independently and graded as mild (< 25%, moderate (25-50%) and marked (>50%). Marked improvement was observed in 10/20(50%) patients. We conclude that pentoxifylline should be considered as first line therapy in all patients with Schamberg's disease.
منابع مشابه
Pentoxifylline in the treatment of pigmented purpuric dermatoses: A randomized, controlled trial
Background and aim: Pigmented purpuric dermatoses are a group of chronic and recurrent skin diseases resulting from lymphocyte-mediated leakage of erythrocytes. No effective treatment has been suggested for these conditions. This study was performed to evaluate the efficacy of oral pentoxiphylline in the treatment of pigmented purpuric dermatoses.Materials and Methods: ...
متن کاملCharacteristics and Clinical Manifestations of Pigmented Purpuric Dermatosis
BACKGROUND Pigmented purpuric dermatoses (PPD) are a spectrum of disorders characterized by a distinct purpuric rash. Although PPD can be easily diagnosed, the disease entity remains an enigma and a therapeutic challenge. OBJECTIVE The purpose of this study was to investigate the characteristics and clinical manifestations of PPD and to elucidate the relationship between assumed etiologic fac...
متن کاملEfficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients
Background: Diabetic nephropathy is considered to be the most common cause of end stage renal disease (ESRD). Proteinuria is declared as the most marked risk factor in progression towards ESRD. The aim of this study was to evaluate the efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients. Methods: From May 2007 to June 2008, this randomized clinical trial study w...
متن کاملConservative Drug Treatment in Patients With Moderately Severe Chronic Occlusive Peripheral Arterial Disease
A double-blind, parallel group, multicenter clinical trial of pentoxifylline compared with placebo enrolled 150 patients with moderately severe chronic occlusive arterial disease (COAD) at three centers in Scandinavia. The study consisted of a 4-6 week single-blind, placebocontrolled run-in phase, during which the stabilization of the initial claudication distance of all patients was assessed b...
متن کاملEffects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease
Background: It was hypothesized that the use of Pentoxifylline would increase arterial O2 saturation and increase exercise tolerance in patients with Chronic Obstructive Pulmonary Disease (COPD). Methods: We tested this hypothesis in 23 patients with COPD and pulmonary hypertension. Patients were randomized to receive Pentoxifylline or placebo, each for a 12-week period, in a prospectiv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Indian journal of dermatology, venereology and leprology
دوره 69 1 شماره
صفحات -
تاریخ انتشار 2003